Liver fibrosis markers in alcoholic liver disease

Lech Chrostek, Anatol Panasiuk

Abstract

Alcohol is one of the main factors of liver damage. The evaluation of the degree of liver fibrosis is of great value for therapeutic decision making in patients with alcoholic liver disease (ALD). Staging of liver fibrosis is essential to define prognosis and management of the disease. Liver biopsy is a gold standard as it has high sensitivity and specificity in fibrosis diagnostics. Taking into account the limitations of liver biopsy, there is an exigency to introduce non-invasive serum markers for fibrosis that would be able to replace liver biopsy. Ideal serum markers should be specific for the liver, easy to perform and independent to inflammation and fibrosis in other organs. Serum markers of hepatic fibrosis are divided into direct and indirect. Direct markers reflect extracellular matrix turnover. These markers should correlate with dynamic changes in fibrogenesis and fibrosis resolution. The assessment of the degree of liver fibrosis in alcoholic liver disease has diagnostic and prognostic implications, therefore noninvasive assessment of fibrosis remains important. There are only a few studies evaluating the diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with ALD. Several noninvasive laboratory tests have been used to assess liver fibrosis in patients with alcoholic liver disease, including the hyaluronic acid, FibroTest, FibrometerA, Hepascore, Forns and APRI indexes, FIB4, an algorithm combining Prothrombin index (PI), α2-macroglobulin and hyaluronic acid. Among these tests, Fibrotest, FibrometerA and Hepascore demonstrated excellent diagnostic accuracy in identifying advanced fibrosis and cirrhosis, and additionally, Fibrotest was independently associated with survival. Therefore, the use of biomarkers may reduce the need for liver biopsy and permit an earlier treatment of alcoholic patients.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Liver fibrosis markers; Alcoholic liver disease

Core tip: Monitoring the stage of liver fibrosis in alcohol abusing persons is important in order to undertake proper therapeutic decisions. The usefulness of liver biopsy in the diagnostics of liver fibrosis is indisputable with the only limitation being its invasive character. Thus, non-invasive tests and biochemical markers determining the stage and dynamics of liver fibrosis in alcoholic liver disease are of great significance.

INTRODUCTION

The diagnosis of alcoholic liver disease (ALD) is based on the following features: history of alcohol abuse, clinical evidence of liver disease and the results of laboratory tests. First, alcoholic patients develop fatty liver, and then more severe consequences such as perivenular fibrosis and alcoholic hepatitis can occur. The most common clinical sign of alcoholic fatty liver is hepatomegaly, but
the majority of patients are asymptomatic. The presence of steatosis in alcoholic liver disease is associated with progression of fibrosis and with necroinflammatory lesions. The precursors of fibrosis are necrosis and inflammation, albeit the cirrhosis commonly develops without overt alcoholic hepatitis. Portal fibrosis can rapidly develop to alcoholic cirrhosis. The incidence of cirrhosis in patients with alcoholic hepatitis is nine times higher than in those with fatty liver. Nevertheless, alcoholic hepatitis develops in only a fraction of heavy drinkers. The prevalence of alcoholic steatohepatitis (ASH) in alcoholics was about 10%-35%. Taking into account the fact that about 30%-35% of heavy drinkers developed advanced forms of ALD such as advanced fibrosis and cirrhosis, the prevalence of presumed and confirmed fibrosis in alcoholic liver disease is established in 7% and 8%, respectively. In another study, advanced fibrosis (F2-F4) confirmed by biopsy examination was present in 63% of patients with chronic alcoholic liver disease.

The treatment of ALD is focused on the psychological and behavioral effects of alcohol consumption, but should also affect severe medical complications. The detection of precursor lesions facilitates early intervention to prevent irreversible liver damage. Therefore, the evaluation of the degree of liver steatosis, fibrosis, and ASH is of great value for therapeutic decision making in patients with ALD. Staging of chronic liver disease, especially liver fibrosis, is essential to define prognosis and management of the disease. According to the METAVIR classification, fibrosis is defined as two stages that significantly modify the management of liver disease. There is advanced fibrosis which is defined as \( F \geq 2 \), and cirrhosis defined as \( F \geq 4 \).

Liver biopsy, which is considered a gold standard for evaluation of the stage of liver fibrosis, is an invasive procedure and leads to complications in 0.6%-5.0% of patients. Additionally, the liver samples can be a cause of diagnostic error, e.g., in almost 30% of patients with chronic hepatitis C provided we underestimate the stage of liver fibrosis. There are three limitations that prevent its use as a routine clinical tool. The fibrosis staging system is not appropriate to describe the linear relationship between amount of fibrosis and fibrosis stage, sampling error and inter-observer variation. On the other hand, biopsy is not recommended for alcohol dependent patients with symptoms of alcoholic liver disease. Taking into account these limitations of liver biopsy, there is an urgent need to introduce non-invasive serum markers for fibrosis that are in a position to replace liver biopsy. Additionally, liver biopsy is not useful for regular testing for fibrosis progression and effectiveness of the therapy. There are several non-invasive imaging techniques for fibrosis evaluation. These include positron emission tomography, transient elastography, and magnetic resonance imaging. In the past decade, serum tests, as non-invasive assessment of liver fibrosis that can accurately evaluate degree of liver fibrosis, were introduced. Serum markers are offered as an alternative to liver biopsy as less invasive but effective in the diagnosis, prognosis and management of liver disease. The diagnostic performance of serum markers in chronic hepatitis C and non-alcoholic liver disease have been reported many times but just a few times in ALD.

**SERUM MARKERS**

Ideal serum markers should be specific for the liver, freely available and easy to measure, independent of inflammation, not influenced by excretion, capable of identifying the stage of fibrosis and correlate with dynamic changes in fibrogenesis and fibrosis resolution. Serum markers of hepatic fibrosis can be divided into direct or indirect. Indirect markers reflect alterations in hepatic function, e.g., platelet count, coagulation factors and transaminases. Direct markers of fibrosis reflect extracellular matrix turnover. These include the products of matrix synthesis or degradation and the enzymes involved in these processes. The markers of matrix deposition are procollagen \( \text{C terminal} \), procollagen \( \text{N terminal} \), tenasin, tissue inhibitor of metalloproteinases, and tumor growth factor-\( \beta \). The markers of matrix removal are procollagen IV \( \text{C peptide} \), procollagen IV \( \text{N peptide} \), collagen IV, undulin, matrix metalloproteinases, urinary desmosine, and hydroxylysylpyridinoline.

There are only a few studies evaluating the diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with ALD. The first generation panel is the PGA index, which includes the Prothrombin index (PI), Gamma-glutamyl transferase (GGT) and Apolipoprotein A1. When the PGA index involves \( \alpha_2 \)-macroglobulin it is called the PGA-A index. FibroTest, Hepascore and Fibrometer\(A \) are second generation panel tests that provide useful information regarding different fibrosis stages and have discriminating power between mild fibrosis and clinical significant fibrosis, and between advanced fibrosis and cirrhosis. FibroTest combines a panel of five biochemical markers: \( \alpha_2 \)-macroglobulin, apolipoprotein A1, haptoglobin, GGT, and total bilirubin adjusted by age and gender. Fibro Test scores from 0 to 0.10 had 100% negative predictive value for the absence of significant fibrosis (F2 or higher by METAVIR) while scores from 0.60 to 1.00 had > 90% positive predictive value for significant fibrosis (F2 or higher by META VIR) in these processes. There are three limitations that prevent its use as a routine clinical tool. The fibrosis staging system is not appropriate to describe the linear relationship between amount of fibrosis and fibrosis stage, sampling error and inter-observer variation. On the other hand, biopsy is not recommended for alcohol dependent patients with symptoms of alcoholic liver disease. Taking into account these limitations of liver biopsy, there is an urgent need to introduce non-invasive serum markers for fibrosis that are in a position to replace liver biopsy. Additionally, liver biopsy is not useful for regular testing for fibrosis progression and effectiveness of the therapy. There are several non-invasive imaging techniques for fibrosis evaluation. These include positron emission tomography, transient elastography, and magnetic resonance imaging. In the past decade, serum tests, as non-invasive assessment of liver fibrosis that can accurately evaluate degree of liver fibrosis, were introduced. Serum markers are offered as an alternative to liver biopsy as
Any disorder associated with extrahepatic fibrosis; cardiovascular HIV co-infection

47 (SE = 0.7)

Ⅲ

47.1 (SE = 0.7)

Alcohol consumption

July 7, 2014

47 (SD = 10.3)

18-74

at least 50 g/d over the previous 5 yr (mean: 94 g/d ± 50)

at least 50 g/d over the previous year

Concomitant liver disease, HIV antibodies, immune-suppression, hepatic surface antigen, antibodies to HCV, associated severe diseases

Concomitant liver disease, human immunodeficiency virus antibodies, immunosuppression

HCV: Hepatitis C virus; LD: Liver disease; HIV: Human immunodeficiency virus.

Table 1 Characteristic of studies concerning alcoholic liver disease

| Study             | Number of patients | Age (yr) | Alcohol consumption | Exclusion criteria                                                                 |
|-------------------|--------------------|----------|---------------------|------------------------------------------------------------------------------------|
| Rosenberg et al[20] (2004) | 64                | 18-74    | No data             | Any disorder associated with extrahepatic fibrosis; cardiovascular disease or cancer; advanced cirrhosis; regular consumption of aspirin; hepatocellular carcinoma or drug-induced liver disease |
| Calès et al[20] (2005) | 95                | 18-74    | ≥50 g/d for the previous 5 yr (mean: 94 g/d ± 50) | Other causes of LD or complicated cirrhosis or received antibiofic treatment within the previous 6 mo |
| Naveau et al[20] (2005) | 221               | 47 (SE = 0.7) | at least 50 g/d over the previous year | Concomitant liver disease, HIV antibodies, immune-suppression, hepatic surface antigen, antibodies to HCV, associated severe diseases |
| Naveau et al[20] (2009) | 218               | 47.1 (SE = 0.7) | ≥50 g/d during the preceding y (mean 146 g/d, SE = 80 g/d for 17 yr) | Concomitant liver disease, human immunodeficiency virus antibodies, immunosuppression |
| Poynard et al[20] (2012) | 218               | 47 (SD = 10.3) | No data             | HIV co-infection                                                                  |

This paper concerns the diagnostic and prognostic values of noninvasive markers in alcoholic liver disease and is based on the study of Calès et al[20] (2005), Naveau et al[20,22] (2005, 2009) and Poynard et al[20] (2012), Rosenberg et al[20] (2004). Inclusion and exclusion criteria were given in Table 1.

The following parameters were assessed: alanine aminotransferase, AST, GGT, bilirubin, PI, α-2 macroglobulin, apolipoprotein A1, haptoglobin, HA, FibroTest, Hepascore, FibrometerA, FIB-4, Forns and APRI indexes, an algorithm combining age, hyaluronic acid, amino-terminal propeptide of type III collagen (P III NP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). In these studies patients were classified according to the severity of fibrosis. Advanced fibrosis was defined as stage F2 or higher according to METAVIR scoring system and cirrhosis as stage F4.

**PRESENCE OF FIBROSIS**

The majority of patients with alcoholic liver disease (93%) had fibrosis; 69.5% had clinically significant fibrosis (F2 or higher), 31% had cirrhosis, and 29% had alcoholic hepatitis (Naveau 2005). In the recent study of Naveau et al[20] the prevalence of clinically significant fibrosis was 63% (minimal fibrosis in 30% of patients) and the prevalence of cirrhosis was 31%. In the study of Calès et al[20], the distribution of fibrosis was as follows: 46.3% had fibrosis, 41.1% had cirrhosis and 29% had alcoholic hepatitis. In the study of Poynard et al[20] minimal fibrosis was present in 63% of patients and cirrhosis in 31% of patients. Discrepancy between the outcomes of Naveau et al[20,22], and Calès et al[20] and Poynard et al[20] should be attributed to different lengths of liver specimen taken by biopsy, 18.4 mm (SD = 6.0) in the study of Calès et al[20] and 15.0 mm (SE = 0.5) in the study of Naveau et al[20,22] and 15.0 mm (SD = 6.5) in the study of Poynard et al[20].

**DIAGNOSIS OF FIBROSIS**

The performance of tests was expressed by the diagnostic accuracy and by the area under the receiver operating characteristic (AUROC). For predicting fibrosis and cirrhosis the sensitivity, specificity, positive predictive values (PPV) and negative predictive values (NPV) were calculated.

According to the results of Naveau et al[20,22] AUROC of FibroTest for the detection of moderate to severe fibrosis (F2-F4) was higher for patented biomarkers (FibroTest, Fibrometer A and Hepascore) than for non patented scores (Forns, APRI and FIB4) (Table 2). The accuracy of these tests for discriminating between advanced (stage F2 or higher) versus non-advanced fibrosis (stage F < 2) reached the same value of AUROC = 0.83. For the diagnosis of cirrhosis (F4) the AUROC of patented biomarkers was higher than that of non patented. The diagnostic values of Fibrometer A and Hepascore did not differ from that of FibroTest for advanced fibrosis and cirrhosis. There were also no differences between...
diagnostic accuracy for FibroTest and HA. These results confirm previous observations that serum HA had good diagnostic values for the diagnosis of cirrhosis[20]. As for other tests, only the apolipoprotein A1 and α-2 macroglobulin had independently predictive values of significant fibrosis (from multivariate analysis). The results indicate that the FibroTest had the highest sensitivity for the detection of cirrhosis, because all cirrhotic patients had FibroTest scores ≥ 0.3 (sensitivity and NPV = 100%). For advanced fibrosis (F2-F4) FibroTest scores ≥ 0.3 had lower sensitivity (84%) and NPV (70%). Therefore, the patients with a score < 0.3 had a low probability of cirrhosis. When the score increased above 0.7, sensitivity and NPV for the diagnosis of advanced fibrosis and cirrhosis decreased but the specificity and PPV increased. 91% of patients with FibroTest score > 0.7 had cirrhosis. There was a significant concordance between FibroTest and biopsy with intra-class coefficient of correlation = 0.961 for F4 and 0.899 for F1[23]. Most discordances between FibroTest and liver biopsy were attributable to errors in biopsy interpretation. The study of Naveau et al[22] showed significant correlation between fibrosis stages and FibroTest (R = 0.71), FibrometerA (R = 0.72) and Hepascore (R = 0.71). All three tests (Fibrotest, FibrometerA, Hepascore) demonstrated excellent diagnostic accuracy in identifying advanced fibrosis and cirrhosis.

According to study of Calès et al[20], the AUROC for clinically significant fibrosis (F2 or higher) in a test combining PI, α-2 macroglobulin, hyaluronic acid and age was higher than that of FibroTest (Table 2). The diagnostic indexes of these blood tests for predicting clinically significant fibrosis were: 91.8% for sensitivity, 92.6% for specificity, 96.6% for PPV and 83.3% for NPV.

The performance of the algorithm of panel serum markers (HA, PIINP and TIMP-1) was compared with histologic staging[21]. The AUC for the differentiation of “mild” and “moderate/severe” alcoholic liver disease (Scheuer stages 0-2 vs 3 and 4) was 0.944 and was higher than that for hepatitis C and for NAFLD. In ALD, for detecting fibrosis stage 3 or 4, using a threshold score of 0.087, the sensitivity and NPV was equal 100%, while a threshold of 0.431 yielded a sensitivity of 93.3%, speci-

| Table 2 Area under the curves receiver operating characteristic for the diagnosis of fibrosis in patients with alcoholic liver disease |
|-----------------|---------------------|---------------------|
| Test            | F2-F4 vs F0-F1      | F4 vs F0-F3          |
| FibroTest[21]   | 0.83 (95%CI: 0.77-0.88) | 0.94 (95%CI: 0.90-0.96) |
| FibrometerA[21] | 0.83 (95%CI: 0.77-0.87) | 0.94 (95%CI: 0.90-0.97) |
| Hepascore[21]   | 0.83 (95%CI: 0.77-0.88) | 0.92 (95%CI: 0.87-0.97) |
| Forns[21]       | 0.38 (95%CI: 0.30-0.46) | 0.38 (95%CI: 0.27-0.47) |
| APRI[21]        | 0.59 (95%CI: 0.51-0.67) | 0.67 (95%CI: 0.59-0.75) |
| FIB-4[21]       | 0.70 (95%CI: 0.62-0.76) | 0.80 (95%CI: 0.72-0.86) |
| FibroTest[4]    | 0.84 ± 0.03 (SD)    | 0.95 ± 0.01 (SD)     |
| Hyaluronic acid[4] | 0.79 ± 0.03 (SD)    | 0.93 ± 0.02 (SD)     |
| The algorithm combining PI, α-2 macroglobulin and hyaluronic acid[4] | 0.962 ± 0.018 (SD) |

| PROGNOSTIC VALUE |
|------------------|
| Hazard function, log-rank test, and proportional hazard regression analysis were used for validation of liver fibrosis biomarkers and assessing liver fibrosis progression in alcoholic liver disease[22]. The biomarkers prognostic value of fibrosis was also estimated in survival analysis[21]. The 5-year and 10-year survival or non-liver related death were main endpoints used to compare the prognostic value of biomarker with histological staging. Survival was calculated from the date that the biomarkers were carried out to the endpoint date. According to data presented by Naveau et al[22], the cumulative global survival, regardless the cause of death, at 5-year survival reached a value of 79 ± 3% and at 10-years survival reached 62 ± 4%. In turn, the cumulative survival and non-liver-related death was 84 ± 3% at 5-years survival and 78 ± 3% at 10-years survival.

Survival was tested according to the three categories of baseline FibroTest. At a cut-off of FibroTest value < 0.32 (no or minimal fibrosis) 5-years survival or non-liver-related death was 98.7%, at baseline FibroTest value > 0.32 and at < 0.58 (moderate fibrosis) it was 92.1%, and at baseline FibroTest value > 0.58 (severe fibrosis) it was 68.3%[22]. At cut-off of FibroTest value < 0.32 (no or minimal fibrosis) 10-years survival or non-liver-related death was 92.0%, at baseline FibroTest value > 0.32 and < 0.58 (moderate fibrosis) it was 87.3%, and at baseline FibroTest value > 0.58 (severe fibrosis) the survival or non-liver-related death was 62.6%.

The accuracy of biomarkers and liver biopsy for the prognosis of patients with ALD was as follows: FibroTest, FibrometerA and Hepascore have AUROC (diagnostic accuracy) than Pugh scores and non-patented markers (FIB-4, APRI and Forns), but the prognostic values of FibroTest, FibrometerA and Hepascore do not significantly differ from biopsy staging. Additionally, FibroTest was well associated with overall survival and
survival or non-liver-related deaths.\(^{[23]}\)

The estimation of liver fibrosis progression (LFP) to cirrhosis in alcoholic fatty liver disease could be done by time-dependent statistics and non-invasive biomarkers such as FibroTest that can be used as an alternative to liver biopsy. The transition of fibrosis to cirrhosis and its complications are always due to mortality associated with ALD.\(^{[24]}\) If the exposure time is known, one biopsy is necessary to estimate the transition rate from normal liver to minimal fibrosis stage (it concerns chronic hepatitis C). Poynard et al.\(^{[25]}\) proposed the time-dependent statistics to assess LFP from birth to first biopsy in chronic liver disease. According to the results of Poynard et al.\(^{[25]}\), the transition rate to minimal fibrosis (F1 in METAVIR scores for biopsy) in ALD estimated by biopsy and FibroTest is concordant with intra class coefficient ICC = 0.864. Biopsy and FibroTest were also in significant concordance for estimation of LFP to cirrhosis, with ICC = 0.970. A more rapid transition of LFP to minimal fibrosis and cirrhosis was observed for men with ALD, for both biopsy and FibroTest. The multivariate analysis showed the similar transition rates to cirrhosis in ALD and non-alcoholic fatty liver disease (NAFLD) using biopsy and FibroTest, but the transition to minimal fibrosis in ALD was higher than in NAFLD using FibroTest.\(^{[24]}\)

In summary, patented biomarkers (FibroTest, FibrometerA and Hepascore) and liver biopsy similarly predict overall survival in alcoholic liver disease. However, they more accurately predict non-liver related survival and death in ALD. FibroTest allows the estimation of liver fibrosis progression in alcoholic liver disease similar to liver biopsy.

**CONCLUSION**

Several noninvasive laboratory tests have been used to assess liver fibrosis in patients with alcoholic liver disease, including the hyaluronic acid, FibroTest, FibrometerA, Hepascore, Forns and APRI indexes, FIB4, an algorithm combining PI, α-2 macroglobulin and hyaluronic acid. The assessment of the degree of liver fibrosis in alcoholic liver disease has diagnostic and prognostic implications and thus, noninvasive assessment of fibrosis remains important. Among these tests, Fibrotest, FibrometerA and Hepascore demonstrated excellent diagnostic accuracy in identifying advanced fibrosis and cirrhosis, and additionally, Fibrotest was independently associated with survival. Therefore, the use of biomarkers may reduce the need for liver biopsy and permit an earlier treatment of alcoholic patients.

**REFERENCES**

1. **Lieber CS.** Medical disorders of alcoholism. *N Engl J Med* 1995; 333: 1058-1065 [PMID: 7675050 DOI: 10.1056/NEJM199510193331607]

2. **Lieber CS.** Alcoholic liver injury: pathogenesis and therapy in 2001. *Pathol Biol* (Paris) 2001; 49: 738-752 [PMID: 11762157 DOI: 10.1016/S0369-8114(01)00239-5]

3. **Teli MR, Day CP, Burt AD, Bennett MK, James OF.** Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. *Lancet* 1995; 346: 987-990 [PMID: 7475591 DOI: 10.1016/S0140-6736(95)90685-7]

4. **Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messoud D, Beuzen F, Capron F, Thabut D, Munteanu M, Chaput JC, Poynard T.** Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. *Clin Gastroenterol Hepatol* 2005; 3: 167-174 [PMID: 15704501 DOI: 10.1016/S1542-3565(04)00625-1]

5. **Wormer TM, Lieber CS.** Perivascular fibrosis as precursor lesion of cirrhosis. *JAMA* 1985; 254: 627-630 [PMID: 4008897]

6. **Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S, ASH and NASH.** *Dig Dis* 2011; 29: 202-210 [PMID: 21734385 DOI: 10.1159/00032886]

7. **Gao B, Bataller R.** Alcoholic liver disease: pathogenesis and new therapeutic targets. *Gastroenterology* 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]

8. **Poynard T, Lebray P, Ingiliz P, Varaut A, Varsat B, Ngo Y, Norha P, Munteanu M, Drane F, Messoud D, Bismut F, Carrau JP, Massard J, Ratziu V, Giordaniella JP.** Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *BMJ Gastroenterol* 2010; 10: 40 [PMID: 20412588 DOI: 10.1186/1471-230X-10-40]

9. **Bedossa P, Poynard T.** An algorithm for the grading of activity in chronic hepatitis C. The METAIVIR Cooperative Study Group. *Hepatology* 1996; 24: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]

10. **Perrault J, McGill DB, Oitt BJ, Taylor WF.** Liver biopsy: complications in 1000 inpatients and outpatients. *Gastroenterology* 1978; 74: 103-106 [PMID: 618417]

11. **Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS.** A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.05346]

12. **Rossi E, Adams LA, Bulsara M, Jeffrey GP.** Assessing liver fibrosis with serum marker models. *Clin Biochem Rev* 2007; 28: 3-10 [PMID: 17603636]

13. **Afzhal NH, Nunes D.** Evaluation of liver fibrosis: a concise review. *Ann J Gastroenterol* 2004; 99: 1160-1174 [PMID: 15180741 DOI: 10.1111/j.1572-0241.2004.30110.x]

14. **Poynard T, Aubert A, Bedossa P, Abella A, Naveau S, Paraf F, Chaput JC.** A simple biological index for detection of alcoholic liver disease in drinkers. *Gastroenterology* 1991; 100: 1397-1402 [PMID: 1672899 DOI: 10.1016/0016-8278(91)90592-8]

15. **Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. *Dig Dis Sci* 1994; 39: 2426-2432 [PMID: 7525168 DOI: 10.1007/BF02087661]

16. **Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T.** Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. *Lancet* 2001; 357: 1069-1075 [PMID: 11299757 DOI: 10.1016/S0140-6736(00)04258-6]

17. **Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G.** Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. *Clin Chem* 2003; 49: 450-454 [PMID: 12600957 DOI: 10.1377/49.3.450]

18. **Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP.** Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. *Clin Chem* 2005; 51: 1867-1873 [PMID: 16055434 DOI: 10.1377/clinchem.2005.048389]

19. **Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pisto R, Ferrari A, Alberti A.** Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. *J Hepatol* 2006; 44: 686-693 [PMID: 16760363]
20 Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-1381 [PMID: 15317693 DOI: 10.1002/hep.20935]

21 Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992 [PMID: 12297848]

22 Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M, Balian A, Njiké-Nakseu M, Perlemuter G, Poynard T. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105 [PMID: 19053048 DOI: 10.1002/hep.22576]

23 Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol 2012; 57: 541-548 [PMID: 22612998 DOI: 10.1016/j.jhep.2012.04.025]

24 Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppant D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713 [PMID: 15578508 DOI: 10.1016/j.gastro]

25 Regov A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrropoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]

26 Tsutsumi M, Urashima S, Takase S, Ueshima Y, Tsuchishima M, Shimanaka K, Kawahara H. Characteristics of serum hyaluronate concentrations in patients with alcoholic liver disease. Alcohol Clin Exp Res 1997; 21: 1716-1721 [PMID: 9438536]

27 Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997; 58: 486-494 [PMID: 9273913]

28 Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Munteanu M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-265 [PMID: 12586290 DOI: 10.1016/S0168-8278(02)00413-0]

P- Reviewers: Fahrial Syam AF, Leardkamolkarn V, Liu ZW, Sunbul M, Xia SH, Zhu X S- Editor: Qi Y L- Editor: O’Neill M E- Editor: Wang CH
